{
    "clinical_study": {
        "@rank": "168139", 
        "arm_group": {
            "arm_group_label": "FTC/TDF for PrEP", 
            "description": "This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication."
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, 3-year observational study to describe drug utilization in uninfected\n      individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)\n      (Truvada\u00ae) for a pre-exposure prophylaxis (PrEP) indication.\n\n      An electronic source of pharmacy/medical encounter information will be used to assess the\n      demographics and other characteristics of the subjects prescribed FTC/TDF or its components\n      in a prospective fashion. The data provider will supply all the de-identified information\n      regarding each visit/interaction that the subject has had with the health system and all the\n      diagnoses and medications that he UI has had prospectively and retrospectively for the\n      length of time captured by the source selected.\n\n      200 physicians who prescribe FTC/TDF for a PrEP indication will be sampled from the same\n      source."
        }, 
        "brief_title": "A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pre-exposure Prophylaxis for Prevention of HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patient/ Uninfected Individual\n\n          -  Adult (any sex/gender, including transgender) \u226518 years old\n\n          -  Taking FTC/TDF prescribed for any indication or its components Prescriber\n\n          -  Possesses an active health care professional license in good standing, with the\n             authority to prescribe prescription medications, either independently (eg, physician)\n             or under legally permissible arrangements for prescribing under physician supervision\n             (eg, Nurse Practitioner or Physician Assistant)\n\n          -  Practice site is within the USA\n\n          -  Having prescribed FTC/TDF for a PrEP indication\n\n        Exclusion Criteria:\n\n          -  There are no exclusion criteria for individuals or prescribers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This prospective case series is composed of every subject in the database that is exposed\n        to FTC/TDF or its components for any indication.\n\n        Additionally, 200 physicians who prescribe FTC/TDF for a PrEP indication will be randomly\n        sampled from the same source."
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865799", 
            "org_study_id": "GS-US-276-0105"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "FTC/TDF", 
            "PrEP", 
            "Truvada", 
            "Drug utilization"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Foster City", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94404"
                }, 
                "name": "Gilead Sciences, Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA", 
        "overall_contact": {
            "email": "Robertino.Mera@gilead.com", 
            "last_name": "Robertino Mera", 
            "phone": "+1 (650) 522-5056"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Drug utilization of uninfected individuals who are prescribed FTC/TDF for a PrEP indication, including gaps in therapy", 
            "safety_issue": "No", 
            "time_frame": "Month 36"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Demographics (including age, gender and if available, race and ethnicity) and clinical characteristics (including diagnoses, procedures, and laboratory test results) will be summarized by 1) exposure group and 2) overall using descriptive statistics (sample size, mean, standard deviation, median, interquartile range, minimum and maximum) for continuous data, and by the number of participants for categorical data; age will be calculated as age in years at exposure.", 
                "measure": "Demographics and clinical characteristics of uninfected individuals who are prescribed FTC/TDF for a PrEP indication", 
                "safety_issue": "No", 
                "time_frame": "Months 6, 12, 18, 24, 30, and 36"
            }, 
            {
                "description": "Demographics (including gender, medical degree, medical specialty, number of years in medical practice, and setting of care) of prescribers of FTC/TDF for a PrEP indication will be summarized using descriptive statistics (sample size, mean, standard deviation, median, interquartile range, minimum and maximum) for continuous data and by the number prescribers for categorical data.", 
                "measure": "Demographics of prescribers of FTC/TDF for a PrEP indication", 
                "safety_issue": "No", 
                "time_frame": "Months 6, 12, 18, 24, 30, and 36"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}